Clinical outcomes of the use of subcutaneous daratumumab for donor-derived cell-free DNA guided treatment of antibody mediated rejection in asian kidney transplant recipients at the Singapore General Hospital

Rituxan (rituximab) - Roche

Darzalex Faspro (daratumumab and hyaluronidase-fihj) - J&J

Jingfei (felzartamab) - Biogen

Terence Kee1,2; Ian Tatt Liew1; Carolyn Tien1; Quan Yao Ho1; Sobhana Thangaraju1,2

Sep 17, 2026